Michela Gallagher

Company: AgeneBio Inc.

Job title: Founder

Seminars:

Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 3:00 pm

Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical & cognitive progression (CDR sum of boxes), brain atrophy was reduced by AGB101 compared to placebo in a 78-week double-blind randomized controlled study Topography of this effect was consistent with the prodromal phase of…Read more

day: Clinical & Commercial Track PM